Warm Autoimmune Hemolytic Anemia Market Size Expected to Grow Major Growth by 2034, According to DelveInsight | Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon

DelveInsight has released a new report, "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Explore epidemiology trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report
• On 24 October 2025, Sanofi conducted a Phase 3 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA.
• Among the 7MM, the US accounted for the highest prevalent cases of autoimmune hemolytic anemia in 2023, with around 57,000 cases; these cases are expected to increase during the forecast period.
• Among gender-specific prevalent cases of wAIHA, females stand out as major contributors. In 2023, Females accounted for up to 60% cases of wAIHA. These cases are anticipated to increase by 2034 in the US.
• Amongst EU4 and the UK, the total prevalent cases of wAIHA were highest in Germany, while the lowest number of cases were in Spain in 2023.
• According to the estimates, in Japan, it is observed that wAIHA was most prevalent in the =65 year's age group, accounting for over 64% of total cases in 2023.
• The leading Warm autoimmune hemolytic Anemia Companies such as Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others
• Promising Warm autoimmune hemolytic anemia Therapies such as Obexelimab (ZB012), Nipocalimab (M281), and others.

Explore Warm Autoimmune Hemolytic Anemia Treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation in the 7MM
• Total Warm Autoimmune Hemolytic Anemia diagnosed prevalent cases
• Total Warm Autoimmune Hemolytic Anemia prevalent cases
• Warm Autoimmune Hemolytic Anemia Type-specific cases
• Warm Autoimmune Hemolytic Anemia Gender-specific cases
• Warm Autoimmune Hemolytic Anemia Age-specific cases

Download the report to understand which factors are driving Warm Autoimmune Hemolytic Anemia epidemiology trends @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Emerging Drugs
• Obexelimab (ZB012): Zenas BioPharma
Obexelimab is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and Fc?RIIB by obexelimab mimics a naturalantigen-antibody complex and downregulates B-cell activity. In early-stage clinical studies, obexelimab effectively demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Currently, the drug is being evaluated in Phase III (SApHiAre trial) clinical stage of development.

• Nipocalimab (M281): Johnson & Johnson Innovative Medicine
Nipocalimab is a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. Upon administration, nipocalimab targets and binds to FcRn at the IgG binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, nipocalimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation, and prevents IgG-mediated inflammation. Nipocalimab was granted FTD for wAIHA in July 2019 and ODD in December 2019. Currently, the drug is being evaluated in Phase II/III (NCT04119050) clinical stage of development.

Warm Autoimmune Hemolytic Anemia (wAIHA) Market Outlook
The most common therapy and the cornerstone of treatment for Warm Autoimmune Hemolytic Anemia are corticosteroids. If these are ineffective, a splenectomy can be considered. Rituximab has become an option in refractory disease, and the use of immunosuppressors can be helpful in chronic severe refractory cases. While glucocorticoids are considered the first-line treatment in WAIHA, this was empirically derived. Mechanisms of actions include suppression of autoantibody production, reduction in autoantibody affinity, and decreased destruction of erythrocytes by splenic macrophages, perhaps by diminished expression of Fc? receptors.

Get In-Depth Knowledge on Warm Autoimmune Hemolytic Anemia Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Companies
Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others

Scope of the Warm Autoimmune Hemolytic Anemia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Warm Autoimmune Hemolytic Anemia Companies- Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others
• Warm autoimmune hemolytic anemia Therapies such as Obexelimab (ZB012), Nipocalimab (M281), and others.
• Warm Autoimmune Hemolytic Anemia Therapeutic Assessment: Warm Autoimmune Hemolytic Anemia current marketed and Warm Autoimmune Hemolytic Anemia emerging therapies
• Warm Autoimmune Hemolytic Anemia Market Dynamics: Warm Autoimmune Hemolytic Anemia market drivers and Warm Autoimmune Hemolytic Anemia market barriers
• Warm Autoimmune Hemolytic Anemia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Warm Autoimmune Hemolytic Anemia Unmet Needs, KOL's views, Analyst's views, Warm Autoimmune Hemolytic Anemia Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Warm Autoimmune Hemolytic Anemia Market Report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF WAIHA
4. WAIHA MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. wAIHA EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
7. DISEASE BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
9. wAIHA PATIENT JOURNEY
10. EMERGING wAIHA DRUGS
11. WAIHA Market: THE 7MM ANALYSIS
12. wAIHA UNMET NEEDS
13. SWOT ANALYSIS
14. KOL VIEWS
15. wAIHA MARKET ACCESS AND REIMBURSEMENT
16. APPENDIX
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.